Samjin Pharmaceutical announced on the 2nd that it has signed a joint research contract for AI new drug development with Cyclica, a Canadian artificial intelligence new drug development platform company. Through the agreement, Samjin Pharmaceutical will propose to Cyclica multiple drug targets currently under review. Cyclica is going to secure candidate materials that are highly likely to be developed by applying AI-based new drug candidate material discovery platform (Ligand DesignTM) technology.

Lee Soo-min, head of the Samjin Pharmaceutical Research Center, said, "Joint research using AI technology with Cyclica will significantly reduce the time and cost required to develop new drugs. We will coopera